文献速递药物不良反应与药物警戒

法国人群研究中蛋白激酶抑制剂暴露后心力衰竭发生率

Incidence of heart failure following exposure to a protein kinase inhibitor, a French population-based study.
PubMed 文献 · Br J Clin Pharmacol · 2022-11-13

调整后分析显示帕唑帕尼、达沙替尼、芦可替尼、克唑替尼、依维莫司和维莫非尼6种药物与心衰风险显著增加相关。

要点

  • PKI暴露后心衰平均发生率3.38/100人年,中位发生时间155天
  • 帕唑帕尼、达沙替尼、芦可替尼、克唑替尼、依维莫司和维莫非尼与心衰风险显著增加相关
  • 临床使用上述PKI时应监测心衰症状,尤其用药早期

核心结论

  • 研究提供了PKI暴露后心衰发生的知识,帕唑帕尼、达沙替尼、芦可替尼、克唑替尼、依维莫司和维莫非尼与心衰风险显著增加相关。

主要发现

  • 心衰平均发生率为3.38/100人年,中位发生时间155天。
  • 帕唑帕尼调整后风险比(aHR)为2.42(95%CI 1.67-3.52)。
  • 达沙替尼aHR为2.22(95%CI 1.42-3.44)。
  • 芦可替尼aHR为2.11(95%CI 1.69-2.64)。
  • 克唑替尼aHR为1.71(95%CI 1.07-2.72),依维莫司aHR为1.45(95%CI 1.26-1.67),维莫非尼aHR为1.37(95%CI 1.01-1.86)。

临床怎么用

  • 对使用帕唑帕尼、达沙替尼、芦可替尼、克唑替尼、依维莫司或维莫非尼的患者,应关注心衰症状并定期评估心功能。

局限性

  • 敏感性分析结果与主要分析一致,但克唑替尼和维莫非尼的结果在敏感性分析中略高于显著性阈值,需额外研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Pharmacovigilance signals of heart failure (HF) following exposure to protein kinase inhibitors (PKIs) have been detected in recent years. Our aim was to identify the PKIs most frequently associated with the development of HF. METHODS: Using the French National Healthcare Database, all patients newly exposed to a PKI between January 2011 and June 2014 were followed up for 18 months. Specific hospitalization diagnosis and long-term HF-related disease codes were used to identify HF patients. HF incidence rate ratios (IRRs) were measured and adjusted hazard ratios (aHRs) were estimated using a Cox model. Sensitivity analyses were performed to limit the potential indication and competitive risk bias. RESULTS: Thirteen PKIs were studied. Among the 49 714 new PKI users registered during the study period, the mean IRR of HF was 3.38 per 100 person-years, with a median time to onset of 155 days. We found a significant increase in the incidence of HF for six medicinal products: pazopanib (aHR = 2.42, 95% confidence interval [CI] 1.67-3.52), dasatinib (aHR = 2.22, 95% CI 1.42-3.44), ruxolitinib (aHR = 2.11, 95% CI 1.69-2.64), crizotinib (aHR = 1.71, 95% CI 1.07-2.72), everolimus (aHR = 1.45, 95% CI 1.26-1.67) and vemurafenib (aHR = 1.37, 95% CI 1.01-1.86). Sensitivity analyses were consistent with our primary analysis. CONCLUSIONS: The current study provides knowledge on HF following exposure to a PKI. Additional studies could confirm these results for dasatinib, everolimus, pazopanib and ruxolitinib, and particularly for the two medicinal products with results slightly above the significance threshold, namely, crizotinib and vemurafenib, in our sensitivity analyses.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zelmat Y, Conte C, Noize P, et al. Incidence of heart failure following exposure to a protein kinase inhibitor, a French population-based study. Br J Clin Pharmacol. 2022. PMID: 36285576. doi:10.1111/bcp.15576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。